Charles River Laboratories Intl. Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.5 (market cap $14.23B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.47 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 5.1× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| CRL | VTIP | |
|---|---|---|
Market Cap | $14.23B | $73.20B |
Volume | 1,176,885 | 2,511,360 |
Sector | Health | — |
52-Week High | $310.77 | $50.46 |
52-Week Low | $149.93 | $48.38 |
Typical Hold Time | 33 Days | 91 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.475, up 0.03% on the day. Technical indicators show a bearish bias with moving averages signaling sell pressure, while oscillators like the 6-day relative strength index at 15.33 suggest oversold conditions. Recent news highlights its role as an inflation hedge amid rising energy prices and Fed rate hikes. The ETF focuses on short-duration TIPS to minimize interest rate risk, with institutional buying noted in recent SEC filings.
The outlook for VTIP is cautiously positive as a defensive inflation hedge, with real yields at multi-decade highs boosting appeal. However, risks include persistent inflation above the Fed's target and potential volatility from rate uncertainty. Investors seeking low-cost, short-duration inflation protection may find value, but the bearish technical trend warrants monitoring for stability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →